Factors such as unhealthy dietary habits and genetic predispositions contribute to the growing obesity epidemic, further fueling the market's expansion
Studies such as the SUSTAIN and STEP trials have demonstrated their benefits in both glycemic control and weight reduction, positioning GLP-1 agonists as cornerstones in the treatment of metabolic disorders
Oral microbiota and vitamin D impact on oropharyngeal squamous cell carcinogenesis: a narrative literature review
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, exemplifies our dedication to cutting-edge care for managing type 2 diabetes and weight
We routinely appear before the board of medicine, board of nursing, board of pharmacy, board of dentistry, counseling board, and other professional boards
The 2023 international guideline supports metformin for adults with PCOS and BMI 25 kg/m for metabolic outcomes, but inositol is a reasonable alternative or adjunct for women who don't tolerate metformin or prefer a non-pharmaceutical option
